New Leaf Venture Partners leads Series B round for Unum Therapeutics
Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum's board of directors.
11 June 2015•3 mins read
